Saturday 17 October 2026
Export RARE’s income statement to Excel — free account
Ultragenyx Pharmaceutical Inc.
RARE Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 28.1%, EPS grew 23.1% and free cash flow grew 12.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
14.54
0.63
−4.15%
Follow RARE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(325.64%) | (657.14%) | 1,327.47% | 838.86% | |
Piotroski F-Score |
3 | 5 | 3 | 3 | |
| (42.48%) | (37.89%) | (46.70%) | (45.60%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(104.79%) | (70.90%) | (106.65%) | (119.59%) | |
Average Days of Receivables |
65.14 | 85.69 | 65.92 | 101.81 | |
Free Cash Flow per Share |
(4.67) | (4.94) | (5.05) | (4.85) | |
Free Cash Flow |
(466.21) | (487.00) | (508.00) | (494.00) | |
Capital Expenditures |
(20.72) | (21.00) | (11.00) | (9.00) | |
| Other line items | |||||
Cash ROIC |
(107.32%) | (81.17%) | (287.01%) | (49,400.00%) | |
Accounts Receivable Turnover |
6.13 | 4.81 | 6.10 | 4.42 | |
Accounts Payable Turnover |
2.54 | 3.11 | 2.46 | 3.30 | |
Inventory Turnover |
2.03 | 2.25 | 2.18 | 2.29 | |
Average Days of Payables |
152.42 | 103.81 | 139.36 | 117.64 | |
Days of Inventory on Hand |
196.11 | 174.13 | 182.50 | 177.98 | |
Tax Rate |
0.01 | 0.01 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
116.58% | 111.44% | 115.07% | 107.81% | |
Selling, General and Administrative Expense of Revenue |
54.32% | 51.86% | 52.24% | 48.95% | |
Share Based Compensation of Revenue |
24.71% | 22.73% | 21.34% | 19.39% | |
Interest Coverage |
(9.44) | (8.63) | (8.13) | (6.86) | |
Operating CF/Net income |
0.77 | 0.81 | 0.82 | 0.83 | |
Depreciation/Fixed assets |
0.12 | 0.13 | 0.13 | 0.13 | |
Capex/Depreciation |
(0.71) | (0.68) | (0.35) | (0.29) | |
Revenue per Share |
6.32 | 6.83 | 6.66 | 7.04 | |
Operating CF per Share |
(4.47) | (4.73) | (4.94) | (4.76) | |
Capex per Share |
(0.21) | (0.21) | (0.11) | (0.09) | |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.01 |
Columns are period end dates